FREE Webinar
Thursday, November 19, 2020
2:30 - 4:00 PM, Eastern Time
Cancer drug development tends to focus on inhibiting protein activity rather than modulating protein levels. While this approach has seen some success, it comes with challenges, such as long-term resistance and toxicity. Targeted protein degradation offers a potential solution to this problem.
Protein degraders are small molecules that induce degradation and remove deleterious proteins from afflicted cells by modulating E3 ligase ubiquitination activity. In this webinar brought to you by The Scientist and sponsored by PerkinElmer|Cisbio, researchers will discuss how small-molecule degraders work, key points of interest in their design, and their applications in both the laboratory and the clinic.
Topics to be covered
Meet the Speakers:
Daohong Zhou, MD Professor of Pharmacodynamics and Radiation OncologyHarry E. Innes Endowed Professor of Cancer ResearchAssociate Director for Translation and Drug DevelopmentUniversity of Florida Health Cancer CenterUniversity ...
